HPV Message Testing and Social Media Campaign

NCT ID: NCT03747302

Last Updated: 2022-09-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1043 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-12

Study Completion Date

2019-09-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project involves a social media campaign to increase parent's knowledge and acceptance of the HPV (human papillomavirus) vaccine. The current vaccine protects against nine types of HPV, including seven that are known to cause cancer. The Centers for Disease Control and Prevention (CDC) estimates that the current HPV vaccine could prevent 90% of cancer cases caused by HPV, including cases of cervical cancer, oropharyngeal (mouth and throat) cancer, anal cancer, and others. About 150 and 104 cases of HPV-associated cancers are diagnosed each year in New Hampshire and Vermont, respectively-many of which could be prevented through vaccination. Currently, only 49.8% of New Hampshire adolescents and 44.3% of Vermont adolescents were not up-to-date for HPV vaccination as of 2016. This social media campaign is testing a set of campaign messages with parents locally and nationally to see which messages are most effective in improving their knowledge and acceptance of the vaccine. A study survey link will monitor the number of people reached and will measure parental intention to get their children vaccinated against HPV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccine Human Papilloma Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Participants
Participants are not aware of which arm of social messaging they are receiving and whether they are receiving the control message or not

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HPV Messaging

Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.

Group Type EXPERIMENTAL

Social Media Message about HPV and HPV vaccine

Intervention Type OTHER

Messages educate parents with facts about HPV vaccination.

Control Message

Subjects are randomized to receive one of five messages about electronic cigarettes.

Group Type OTHER

Social media message about risk of electronic cigarettes.

Intervention Type OTHER

Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Social Media Message about HPV and HPV vaccine

Messages educate parents with facts about HPV vaccination.

Intervention Type OTHER

Social media message about risk of electronic cigarettes.

Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* parents of children 9-14 years old

Exclusion Criteria

* non-parents
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Norris Cotton Cancer Center

OTHER

Sponsor Role collaborator

Dartmouth-Hitchcock Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ardis Olson, MD

Physician, Professor of Pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ardis L Olson, MD

Role: PRINCIPAL_INVESTIGATOR

Trustees of Dartmouth College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form: Phase 3

View Document

Document Type: Informed Consent Form: Phase 2

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3P30CA023108-38S4

Identifier Type: NIH

Identifier Source: secondary_id

View Link

D18180

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SDH of HPV Vaccine Completion
NCT03709602 COMPLETED
Parents' HPV Stories
NCT06704308 NOT_YET_RECRUITING NA
HPV Vaccine Reduced Dose
NCT06799494 RECRUITING PHASE4
HPV Vaccine Confident Families
NCT06002282 SUSPENDED NA
Usability of HPV Vaccine Reminders
NCT03987490 COMPLETED NA
Immunogenicity of 9-valent HPV Vaccine
NCT05439083 RECRUITING PHASE4